FormsNet3 - Blank Form


 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number:    

 
 
CIBMTR Recipient ID:    

 
 
Today's Date: __ __ __ __ - __ __- __ __  

 
 
Date of HSCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HSCT type (check all that appy): 

 
  

gfedcb
Autologous

 
 

  
gfedcb

Allogeneic, unrelated

 
 

  
gfedcb

Allogeneic, related

 
 

  
gfedcb

Syngeneic (identical twin)

 

Product type (check all that apply): 

 
  

gfedcb
Marrow

 
 

  
gfedcb

PBSC

 
 

  
gfedcb

Cord blood

 
 

  
gfedcb

Other product

 
 
Specify:    

 
 

  
gfedcb

If this is a report of a second or subsequent transplant, check here and continue with question 95.

 
 
1  What was the date of diagnosis of Sickle Cell Anemia? __ __ __ __ - __ __- __ __  

 
 

2  Was the recipient diagnosed with sickle cell disease at birth (i.e., newborn screening)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

3  What is the recipient's sickle cell disease genotype?

    
 nmlkji

Hb SS  

 nmlkji
Hb S beta0 thalassemia  

 nmlkji
Hb SC  

 nmlkji
Hb S beta+ thalassemia  

 nmlkji
other genotype  

 
 
4  Specify other genotype:    

 
 

5  Did the recipient receive red blood cell transfusions at any time prior to the preparative regimen?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  
 
6  Date of first transfusion: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date of first transfusion unknown

 
 

7  Specify the total number of transfusions received prior to the preparative regimen:

    
 nmlkji

< 5  
 nmlkji

5-10  
 nmlkji

>10  

 
 

8  Did the transfusion(s) induce red cell alloimmunization?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

9  Specify the number of alloantibodies detected:

    
 nmlkji

1  
 nmlkji

>=2  
 nmlkji

Unknown  

  Key Fields 

Sickle Cell Anemia Pre-HSCT Data Questions: 1 - 118

Form 2030 R2.0: Sickle Cell Anemia Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2030 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 7



 

Specify the blood group(s) the recipient has developed alloantibodies to: 
 

10  Duffy - Fya

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

11  Kell - K

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

12  Kell - k

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

13  Kidd - Jka

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

14  Kidd - Jkb

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

15  Lewis - Lea

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

16  Lewis - Leb

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

17  MNSs - M

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

18  MNSs - N

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

19  MNSs - S

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

20  MNSs - s

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

21  Rh - C

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

22  Rh - D

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

23  Rh - E

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

24  Rh - e

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

25  Rh - hra

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

26  Other

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
27  Specify:    

 
 

28  Are red cell autoantibodies present?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Form 2030 R2.0: Sickle Cell Anemia Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2030 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 7



 
 

29  Specify the number of autoantibodies detected:

    
 nmlkji

1  
 nmlkji

>=2  
 nmlkji

Unknown  

 
 

30  Was iron chelation therapy performed at any time prior to the preparative regimen?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  
 
31  Date chelation therapy started: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date unknown

 
 

32  Specify the predominant route of administration:

    
 nmlkji

intramuscular  
 nmlkji

intravenous  
 nmlkji

oral  
 nmlkji

subcutaneous  
 nmlkji

other route  
 nmlkji

Unknown  

 
 
33  Specify other route:    

 
 

34  Was a liver biopsy performed at any time prior to the preparative regimen?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  
 
35  Date of most recent liver biopsy: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date unknown

 
 

36  Was hepatitis present?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

37  Specify the severity of hepatitis:

    
 nmlkji

mild  
 nmlkji

moderate  
 nmlkji

severe  
 nmlkji

Unknown  

 
 

38  Was siderosis present?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

39  Specify the severity of siderosis:

    
 nmlkji

mild  
 nmlkji

moderate  
 nmlkji

severe  
 nmlkji

Unknown  

 
 

40  Was fibrosis present?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

41  Specify the severity of fibrosis:

    
 nmlkji

mild  
 nmlkji

moderate  
 nmlkji

severe  
 nmlkji

Unknown  

 
 

42  Were serial liver biopsies performed?

    
 nmlkji

yes  
 nmlkji

no  

 
 

43  Did the liver biopsies show progressive disease?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

44  What was the hepatic iron concentration (HIC)?

    
 nmlkji

Known  
 nmlkji

Unknown  

 
 
45  Specify HIC:    mg/g 

 
 

46  Is a copy of the biopsy report attached?

    
 nmlkji

yes  
 nmlkji

no  

 
 

47  Were pulmonary function tests (PFTs) performed at any time prior to the preparative regimen?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

48  Specify PFT results:

    
 nmlkji

Normal  
 nmlkji

Stage 1 disease  
 nmlkji

Stage 2 disease  
 nmlkji

Stage 3 disease  
 nmlkji

Stage 4 disease  
 nmlkji

Unknown  

 
 

49  Is a copy of the PFT report attached?

    
 nmlkji

yes  
 nmlkji

no  

Form 2030 R2.0: Sickle Cell Anemia Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2030 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 7



 

Specify the sickle cell disease symptoms experienced at any time prior to the preparative regimen: 
 

50  Acute chest syndrome

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

51  Total number of episodes within 2 years prior to the HSCT:

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
52  Number of episodes:    

 
 

53  Total number of episodes within the recipient's lifetime:

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
54  Number of episodes:    

 
 

55  Did the recipient require exchange transfusion?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify any treatment(s) the recipient required for acute chest syndrome: 
 

56  antibiotics

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

57  intubation / mechanical ventilation

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

58  oxygen

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

59  transfusion of red blood cells

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

60  other treatment

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
61  Specify:    

 
 

62  Osteonecrosis

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify joint(s) affected: 
 

63  ankle

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

64  hip

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

65  knee

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

66  shoulder

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

67  spine

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

68  Other

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
69  Specify:    

Form 2030 R2.0: Sickle Cell Anemia Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2030 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 7



 
 

70  Priapism

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

71  Number of episodes experienced in the last 2 years:

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
72  Number of episodes:    

 
 

73  Was surgery performed to correct blood flow?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

74  Seizures

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

75  Sickle nephropathy

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

76  Stroke

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

77  Specify the total number of strokes:

    
 nmlkji

1  
 nmlkji

>=2  
 nmlkji

Unknown  

 
 

78  Vaso-occlusive pain requiring hospitalization within 2 years prior to the HSCT

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

79  Specify the frequency of hospitalization:

    
 nmlkji

<3 instances per year  

 nmlkji
>=3 instances per year  

 nmlkji
Unknown  

 
 

80  Did the recipient receive hydroxyurea at any time prior to the HSCT?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  
 
81  Date hydroxyurea started: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date hydroxyurea started unknown

  
 
82  Date hydroxyurea stopped: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date hydroxyurea stopped unknown

 
 

83  Was hemoglobin electrophoresis performed while the recipient was receiving hydroxyurea?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  

If the recipient received chronic transfusions prior to HSCT, provide pre-transfusion electrophoresis data. 
 
84  Date of electrophoresis: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date of electrophoresis unknown

  

Specify the level of each hemoglobin type: 
 
85  Hb A1:    % 

 
  

gfedcb
Hb A1 not tested while receiving hydroxyurea

  
 
86  Hb A2:    % 

 
  

gfedcb
Hb A2 not tested while receiving hydroxyurea

  
 
87  Hb C:    % 

 
  

gfedcb
Hb C not tested while receiving hydroxyurea

  
 
88  Hb F:    % 

 
  

gfedcb
Hb F not tested while receiving hydroxyurea

  
 
89  Hb S:    % 

 
  

gfedcb
Hb S not tested while receiving hydroxyurea

 
 

90  Other hemoglobin

    
 nmlkji

yes  
 nmlkji

no  

 
 
91  Specify type:    

 
 
92  Level:    % 

Form 2030 R2.0: Sickle Cell Anemia Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2030 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 7



 
 

93  Is a copy of the electrophoresis report attached?

    
 nmlkji

yes  
 nmlkji

no  

 
 

94  Did the recipient experience gonadal dysfunction at any time prior to the preparative regimen?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

95  Was a brain MRI / MRA performed just prior to the preparative regimen?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

96  Specify the MRI / MRA results:

    
 nmlkji

Normal  
 nmlkji

Abnormal  
 nmlkji

Unknown  

 
 

97  Is a copy of the MRI / MRA report attached to this form?

    
 nmlkji

yes  
 nmlkji

no  

 
 

98  Was a EKG performed prior to the preparative regimen?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

99  Specify the EKG results:

    
 nmlkji

Normal  
 nmlkji

Abnormal  
 nmlkji

Unknown  

 
 

100  Is a copy of the EKG report attached to this form?

    
 nmlkji

yes  
 nmlkji

no  

 
 

101  Was an echocardiogram performed prior to the preparative regimen?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

102  Specify the echocardiogram results:

    
 nmlkji

Normal  
 nmlkji

Abnormal  
 nmlkji

Unknown  

 
 

103  Is a copy of the echocardiogram report attached to this form?

    
 nmlkji

yes  
 nmlkji

no  

 
 

104  Was the recipient's serum ferritin level tested at any time prior to the preparative regimen?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

105  Specify the serum ferritin results:

    
 nmlkji

<1,000 ng/mL or µg/L  

 nmlkji
>=1,001 ng/mL or µg/L  

 nmlkji
Unknown  

 
 

106  Was hemoglobin electrophoresis performed just prior to the preparative regimen (not including any electrophoresis reported in question 83)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  

If the recipient received chronic transfusions prior to HSCT, provide pre-transfusion electrophoresis data. 
 
107  Date: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date unknown

  

Specify the level of each hemoglobin type: 
 
108  Hb A1:    % 

 
  

gfedcb
Hb A1 not tested

  
 
109  Hb A2:    % 

 
  

gfedcb
Hb A2 not tested

  
 
110  Hb C:    % 

 
  

gfedcb
Hb C not tested

  
 
111  Hb F:    % 

 
  

gfedcb
Hb F not tested

  
 
112  Hb S:    % 

 
  

gfedcb
Hb S not tested

Form 2030 R2.0: Sickle Cell Anemia Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2030 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 6 / 7



 
 

113  Other hemoglobin type

    
 nmlkji

yes  
 nmlkji

no  

 
 
114  Specify type:    

 
 
115  Level:    % 

 
 

116  Is a copy of the hemoglobin electrophoresis report attached to this form?

    
 nmlkji

yes  
 nmlkji

no  

 
 

117  What was the primary reason for the HSCT?

    
 nmlkji

acute chest syndrome  

 nmlkji
excessive transfusion requirements / iron overload  

 nmlkji
recurrent priapism  

 nmlkji
recurrent vaso-occlusive pain  

 nmlkji
stroke  

 nmlkji
other reason  

 nmlkji
Unknown  

 
 
118  Specify primary reason for HSCT:    

  
 
First Name:    

 
Last Name:    

  
 
Phone number:    

 
Fax number:    

 
 
E-mail address:    

Form 2030 R2.0: Sickle Cell Anemia Pre-HSCT Data  
Center:  CRID: 

                 CIBMTR Form 2030 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 7 / 7